News
RareCyte® selected for the Wellcome Leap In Utero program; will utilize its rare cell liquid biopsy platform to perform breakthrough research to decrease stillbirth rates worldwide
Seattle, WA, November 14, 2022 – RareCyte, Inc., (“RareCyte” or “The Company”) a leading provider of Precision Biology products and services has been selected by Wellcome Leap to participate in the $50M In Utero program to create the scalable capacity to measure, model and predict gestational development, to achieve the goal of reducing global stillbirth rates by half. RareCyte will join world renowned researchers in pursuing this ambitious goal.The GastroIntestinal Research Foundation Launches New Multi-Million Dollar Funding Initiative Aimed at Curing Cancers of the Digestive System
Chicago, IL, Nov 3rd, 2022 - Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the GastroIntestinal Research Foundation (GIRF) has launched a bold initiative, CA CURE, to identify and fund research to improve diagnostics and develop therapeutics focused on immunotherapies and personalized vaccines.RareCyte® reports significant 2021 growth of Precision Biology™ Services business and customer uptake of Orion™ Spatial Biology instruments and reagents
Seattle, WA, January 6th, 2022 - RareCyte Inc., (“RareCyte” or “The Company”) a leading provider of Precision Biology products and services recognized over 100% sales growth in their Services business in 2021. They also saw significant uptake by early adopters of their Orion instruments and consumables by global key opinion leaders in support of fast, subcellular whole slide spatial analysis.RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels
Seattle, WA, September 9, 2021 – RareCyte, Inc. (“RareCyte” or “the Company”) a Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, announced today the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company’s new Orion spatial biology platform and further global expansion for the Company’s portfolio of instruments and consumables.RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignancies
Seattle, WA, June 01, 2021 – RareCyte® announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.RareCyte announces new rare cell detection kit for non-epithelial cancers
Seattle, WA, September 7, 2021 – RareCyte® announces a new rare cell detection kit, The Cell Discovery Kit, which enables custom panel development in your lab for the detection of circulating tumor cells (CTCs) that do not express epithelial markers, such as sarcomas and melanoma, as well as other non-tumor rare cell populations. Together with the AccuCyte® Sample Preparation System, the Cell Discovery Kit provides sensitive and specific rare cell identification.RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer
Seattle, WA, August 26, 2020 – RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.RareCyte® announces the Orion™ spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis
Seattle, WA. July 16, 2020 – RareCyte, Inc., a company focused on providing Precision Biology™ solutions for life sciences, announced today the Orion spatial biology analysis platform applicable to translational and clinical research. Orion is based on a patented and proprietary technology that will accelerate immuno-oncology and infectious disease research. Orion enables comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment in a matter of hours, in contrast to existing technologies that require several days to weeks.Accurate Spike-in of Circulating Tumor Cells into Blood Samples is Essential for Reliable Analysis in Oncology Applications
Berlin, Germany, Lyon, France, and Seattle, WA, USA, June 22, 2020: SCIENION AG and RareCyte Inc. today announced that cellenONE® proved to be a most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENION’s French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay
Seattle, WA, February 27, 2020 - RareCyte announces a new liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression on circulating tumor cells (CTCs) with industry leading sensitivity. PD-L1 is a biomarker that directs checkpoint inhibitor immunotherapy treatment and liquid biopsy offers a noninvasive method to evaluate biomarker expression for treatment selection and patient monitoring in clinical research.Events
AACR 2023
14-19 April, 2023
Orlando, USA
Booth 955
RareCyte team attendance: Alicia Langeway, Xiaocong Chen, Selena Larkin
Contact us to set up a meeting
Event website →
Spatial Biology UK 2023
25-26 April, 2023
London, UK
Booth #17
RareCyte team attendance: Alex Darmoise, Mickael Meyrand
Contact us to set up a meeting
Event website →
Spatial Biology US 2023
6-8 June, 2023
Boston, USA
RareCyte team attendance: Alicia Langeway
Contact us to set up a meeting
Event website →
Digital Path and AI Congress
22-23 June, 2023
New York City, USA
RareCyte team attendance: Alicia Langeway
Contact us to set up a meeting
Event website →
Spatial Biology Congress
6-7 July, 2023
Amsterdam, The Netherlands
RareCyte team attendance: Alex Darmoise, Mickael Meyrand
Contact us to set up a meeting
Event website →
Spatial Biology EU 2023
12-13 September, 2023
Amsterdam, The Netherlands
RareCyte team attendance: Alex Darmoise, Mickael Meyrand
Contact us to set up a meeting
Event website →
